Expert opinion suggests improved management of adverse events in HR-positive HER2-negative breast cancer to optimize adherence and treatment outcomes.
Capivasertib, an AKT inhibitor, approved in combination with fulvestrant for hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer with ≥1 PIK3CA , AKT1 , and/or PTEN alterations, significantly improved progression-free survival in the CAPItello-291 phase 3 trial. However, capivasertib-associated adverse events of diarrhea, rash, and hyperglycemia may require proactive management. This article provides practical recommendations to support prevention and early intervention to optimize adherence and treatment outcomes.
No takes yet. Share an insight, caveat, or question.
Hamilton et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: